

1                   **Emergence of multiple SARS-CoV-2 antibody escape variants in an**  
2                   **immunocompromised host undergoing convalescent plasma treatment**

3  
4   Liang Chen<sup>1</sup>, Michael C Zody<sup>2</sup>, Jose R Mediavilla<sup>1</sup>, Marcus H Cunningham<sup>1</sup>, Kaelea Composto<sup>1</sup>,  
5           Kar Fai Chow<sup>3</sup>, Milena Kordalewska<sup>1</sup>, André Corvelo<sup>2</sup>, Dayna M Oschwald<sup>2</sup>, Samantha  
6   Fennessey<sup>2</sup>, Marygrace Zetkulic<sup>2</sup>, Sophia Dar<sup>3</sup>, Yael Kramer<sup>3</sup>, Barun Mathema<sup>3</sup>, Tom Maniatis<sup>2</sup>,  
7                                   David S Perlin<sup>1</sup>, Barry N Kreiswirth<sup>1</sup>

- 8  
9           1. Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ, USA  
10          2. New York Genome Center, New York, NY, USA  
11          3. Hackensack Medical University Center, Hackensack, NJ, USA.  
12          4. Mailman School of Public Health, Columbia University Irving Medical Center, New York,  
13           NY, USA

14  
15  
16  
17   Corresponding author: Dr. Barry N Kreiswirth, [Barry.Kreiswirth@hmh-cdi.org](mailto:Barry.Kreiswirth@hmh-cdi.org)

20 **Abstract**

21 SARS-CoV-2 Variants of Concerns (VOC), e.g., B.1.351 (20H/501Y.V2) and P1 (20J/501Y.V3),  
22 harboring N-terminal domain (NTD) or the receptor-binding domain (RBD) (e.g., E484K)  
23 mutations, exhibit reduced in vitro susceptibility to convalescent serum, commercial antibody  
24 cocktails, and vaccine neutralization, and have been associated with reinfection. The  
25 accumulation of these mutations could be the consequence of intra-host viral evolution due to  
26 prolonged infection in immunocompromised hosts. In this study, we document the  
27 microevolution of SARS-CoV-2 recovered from sequential tracheal aspirates from an  
28 immunosuppressed patient on tacrolimus, steroids and convalescent plasma therapy, and  
29 identify the emergence of multiple NTD and RBD mutations associated with reduced antibody  
30 neutralization as early as three weeks after infection. SARS-CoV-2 genomes from the first  
31 swab (Day 0) and three tracheal aspirates (Day 7, 21 and 27) were compared at the sequence  
32 level. We identified five different S protein mutations at the NTD or RBD regions from the  
33 second tracheal aspirate sample (21 Day). The S:Q493R substitution and S:243-244LA deletion  
34 had ~70% frequency, while ORF1a:A138T, S:141-144LGVY deletion, S:E484K and S:Q493K  
35 substitutions demonstrated ~30%, ~30%, ~20% and ~10% mutation frequency, respectively.  
36 However, the third tracheal aspirate sample collected one week later (Day 27) was  
37 predominated by the haplotype of ORF1a:A138T, S:141-144LGVY deletion and S:E484K (>  
38 95% mutation frequency). Notably, S protein deletions (141-144LGVY and 243-244LA deletions  
39 in NTD region) and substitutions (Q493K/R and E484K in the RBD region) previously showed  
40 reduced susceptibility to monoclonal antibody or convalescent plasma. The observation supports  
41 the hypothesis that VOCs can independently arise and that immunocompromised patients on  
42 convalescent plasma therapy are potential breeding grounds for immune-escape mutants.

43

44 **Competing Interest Statement**

45 The authors have declared no competing interest.

46

47 **Funding Statement**

48 The study was in part supported by Center for Discovery and Innovation and Hackensack

49 Meridian Health Foundation.

50

51

## 52 **Introduction**

53 After a year of the COVID-19 pandemic, with over 100 million global cases and 2.80 million  
54 deaths, the world is now focused on the biological consequences of the distribution of vaccines  
55 and the spread of “Variants of Concerns” (VOC). Three SAR-CoV-2 VOCs, i.e., B.1.1.7  
56 (20I/501Y.V1), B.1.351 (20H/501Y.V2) and P1 (20J/501Y.V3) carrying the spike protein N501Y  
57 mutation emerged in the UK, South Africa, Brazil and Japan<sup>1</sup>, and have been associated with  
58 high transmissibility due to the increased affinity to the ACE receptor. In each of these viruses,  
59 the spike protein contains clustered mutations in the N-terminal domain (NTD) and the receptor-  
60 binding domain (RBD) (e.g., E484K) regions. Some VOCs carrying these mutations show  
61 reduced *in vitro* susceptibility to convalescent serum, commercial antibody cocktails, and  
62 vaccine neutralization, and have been associated with reinfection<sup>2,3</sup>. The accumulation of these  
63 mutations is assumed to be the consequence of intra-host viral evolution due to prolonged  
64 infection in immunocompromised hosts<sup>4,5</sup>. A recent NEJM report from Choi et al.<sup>4</sup> described the  
65 emergence of antibody escape mutations from an immunocompromised patient 75 days after  
66 infection. Here, we document the microevolution of SARS-CoV-2 recovered from sequential  
67 tracheal aspirates from an immunosuppressed patient on tacrolimus, steroids and convalescent  
68 plasma therapy, and identify the emergence of multiple NTD and RBD mutations associated  
69 with reduced antibody neutralization as early as three weeks after infection.

70

## 71 **Materials and Methods**

### 72 **SARS-CoV-2 detection**

73 Total nucleic acid (TNA) from nasopharyngeal swabs was extracted by the MagNAPure 24  
74 system (Roche Life Science) and Viral RNA from tracheal aspirates was extracted using  
75 QIAamp Viral RNA Mini Kit (Qiagen), following the manufacturer's instructions. SARS-CoV-2

76 detection was performed using the CDI-enhanced COVID-19 test<sup>6</sup>, targeting SARS-CoV-2 E an  
77 N2 genes. The test was approved for use on March 12, 2020 under FDA Emergency Use  
78 Authorization for COVID-19 and has a limit of detection less than 20 viral genome copies per  
79 reaction. A specimen is considered positive if the gene target has a cycle threshold (Ct) value <  
80 40.

81

## 82 **SARS-CoV-2 viral sequencing and genomic analysis**

83 SARS-CoV-2 targeted assay libraries were prepared using the AmpliSeq Library Plus and cDNA  
84 Synthesis for Illumina kits (Illumina) in accordance with manufacturer's recommendations.  
85 Briefly, 20ng of RNA was reverse transcribed followed by amplification of cDNA targets using  
86 the Illumina SARS-CoV-2 research panel (Illumina). The amplicons were then partially digested,  
87 ligated to AmpliSeq CD Indexes, and then amplified using 18 cycles of PCR. Libraries were  
88 quantified using fluorescent-based assays including PicoGreen (Life Technologies), Qubit  
89 Fluorometer (Invitrogen), and Fragment Analyzer (Advanced Analytics). Final libraries were  
90 sequenced on a NovaSeq 6000 sequencer (v1 chemistry) with 2x150bp.

91

92 Short read-data were filtered and processed prior to alignment. Read pairs that did not contain a  
93 single 19bp seed k-mer in common with the SARS-CoV-2 genome reference (NC\_045512.2)  
94 were discarded. Adapter sequences and low quality (Q < 20) bases were trimmed from the  
95 remaining reads, using Cutadapt v2.10<sup>7</sup>. Processed reads were then mapped to the SARS-  
96 CoV-2 genome reference using BWA-MEM v0.7.17<sup>8</sup> and only read pairs with at least one  
97 alignment spanning a minimum of 42 bp in the reference and starting before position 29,862 (to  
98 exclude polyadenine-only alignments) were kept. Genome sequences were determined by  
99 alignment pileup consensus calling with a minimum support of 5 reads using Samtools v1.11

100 and bcftools v1.11<sup>9</sup>. SNP and InDels were called using FreeBayes v1.3.5  
101 (<https://github.com/freebayes>), followed by annotation using SnpEff v4.5<sup>10</sup>. A minimum variant  
102 calling frequency was set to be 5% to identify within host variations.

103  
104 The resulting SARS-CoV-2 viral genome sequences were uploaded to Nextclade server  
105 (<https://clades.nextstrain.org/>) to assign Nextstrain clades<sup>11</sup>. SARS-CoV-2 lineage was  
106 determined using Pangolin v2.3.0 (<https://github.com/cov-lineages/pangolin>) and GISAID clade  
107 is determined based upon the clade specific marker variants from <https://www.gisaid.org><sup>12</sup>. In  
108 addition, 2,282 SARS-CoV-2 genomes with E484K mutation were downloaded from GISAID  
109 database<sup>12</sup> (date as 2/12/2021), and the genomes with less than 1% ambiguous nucleotides  
110 (Ns) and > 28,900 bp were aligned using MAFFT v7.475<sup>12</sup> using default setting. A maximum  
111 likelihood phylogenetic tree was constructed using IQ-TREE v2.1.2<sup>13</sup> with automatic model  
112 selection and 1000-bootstrap replicates. The resulting tree was annotated using ITOL v5<sup>14</sup>.

113

## 114 **Informed consent**

115 Informed consent was obtained from this patient and the study was approved by Hackensack  
116 Meridian Health Institutional Review Board (IRB) under protocol Pro2018-1022.

117

## 118 **Results**

### 119 **Case description**

120 A male in early 50s presented to a Northern Jersey hospital with fever, productive cough,  
121 generalized myalgias, and progressive shortness of breath for 4 days (**Fig1A**). He had history of  
122 deceased donor kidney transplant for end-stage renal disease (ESRD) secondary to HTN,

123 complicated by cellular graft rejection and recurrent collapsing focal segmental  
124 glomerulosclerosis. On physical examination, the patient had fever of temperature 102.3F, O2  
125 Saturation 90% on 100% non-rebreather. His examination was significant for tachypnea, but  
126 otherwise unremarkable. He was admitted under the suspicion of COVID-19 pneumonia. His  
127 medications were significant for his immunosuppressive regime of mycophenolic acid,  
128 prednisone, and tacrolimus along with multiple anti-hypertensive medications.

129  
130 COVID-19 was confirmed to be positive by RT-PCR (Day 0). Chest X-Ray (CXR) revealed  
131 dense infiltrates bilaterally reflective of his viral pneumonia. Given his multiple comorbidities,  
132 immunosuppressed status, and work of breathing, he was admitted to the ICU for high flow and  
133 awake proning and was started on broad spectrum meropenem treatment. His anti-  
134 hypertensives were discontinued due to his normotension, and his immunosuppressive regime  
135 was continued except for mycophenolate given the likelihood of serious infection.

136  
137 He was treated with high-titer convalescent plasma (Day 1) and tocilizumab (Day 2). Due to his  
138 worsening respiratory status, the patient was intubated (Day 2). Antibiotics were switched to  
139 vancomycin and piperacillin-tazobactam and then discontinued as the patient was afebrile (Day  
140 3). The patient was found to have bilateral deep venous thrombosis and was started on  
141 therapeutic heparin (Day 3). Due to worsening hypoxic respiratory failure despite complete  
142 support from mechanical ventilation, the patient was subsequently cannulated and placed on  
143 veno-venous extra-corporeal oxygenation (ECMO) (Day 5). He went into rapid atrial flutter as  
144 well and was started on intravenous amiodarone (Day 5). His renal failure attributed to multiple  
145 factors such as his tacrolimus, COVID-19 injury, and hypotension slowly began to improve.  
146 Oxygenation began to improve and stabilize, leading to tracheostomy (Day 16) and ECMO

147 explantation (Day 20). The patient, however, became febrile and septic with *Enterococcus*  
148 bacteremia and *Proteus mirabilis* pneumonia and was restarted on vancomycin and piperacillin-  
149 tazobactam (Day 20). He subsequently developed septic shock and was started on  
150 vasopressors (Day 21). Following the antibiogram, antibiotics were de-escalated to ampicillin  
151 (Day 21) and continued for a 7-day course. The septic shock resolved, and the patient was re-  
152 started on his anti-hypertensives once his blood pressure began to remain stable. His course  
153 continued to be complicated by periodic desaturations and wide and narrow complex  
154 tachycardia, anemia, and thrombocytopenia. He slowly improved permitting ventilation and  
155 sedation weaning. As his dysphagia was unresolved during his recovery, percutaneous  
156 endoscopic gastrostomy (PEG) tube was placed (Day 28) to improve nutritional status. He was  
157 transferred to the step-down unit as he continued to recover (Day 49) and was discharged to a  
158 long-term care facility (Day 64) requiring ventilatory support only at night. Unexpectedly, the  
159 patient expired presumably due to hypoxic respiratory failure secondary to his COVID-19  
160 pneumonia (Day 94).

161

## 162 **Genomic analysis**

163 SARS-CoV-2 positive qRT-PCR results (**Table 1**) were obtained from three nasopharyngeal  
164 swab samples (on Day 0, 34 and 41) and three tracheal aspirates (on Day 7, 21 and 27); the  
165 first swab and the three tracheal aspirates were available for viral genome sequencing (**Fig1A**).  
166 The genotype of the initial swab and tracheal aspirate (Day 7) were identical. The genomes of  
167 these two samples harbored 14 mutations (versus Wuhan-Hu-1), and were assigned as  
168 Nextstrain clade 20C, Pangolin lineage B.1.369 and GISAID clade GH, distinct from the three  
169 501Y VOCs (**Fig1B, C**). The second tracheal aspirate specimen (from Day 21) showed five  
170 different S protein mutations at the NTD or RBD regions. The S protein Q493R substitution and  
171 243-244LA deletion had ~70% frequency, while ORF1a A138T, S protein 141-144LGVY



172 deletion, E484K and Q493K substitutions demonstrated ~30%, ~30%, ~20% and ~10%  
173 mutation frequency, respectively (**Fig1D**). However, the third tracheal aspirate sample collected  
174 one week later (Day 27) was predominated by the haplotype of ORF1a:A138T, S:141-144LGVY  
175 deletion and S:E484K (> 95% mutation frequency) (**Fig1D**).

176  
177 The 141-144LGVY and 243-244LA deletions are located in the recently described “Recurrent  
178 Deletion Region” (RDR) 2 and 4<sup>15</sup>, respectively, within the NTD of the spike protein. The  
179 appearance of deletions in the RDR region of the spike protein has been observed during  
180 prolonged infections in immunocompromised patients and proposed as a mechanism that  
181 evades the proofreading activity of the virus and accelerates adaptive evolution. The 141-  
182 144LGVY and 243-244LA deletions confer resistance to NTD specific monoclonal antibody in  
183 neutralization assays<sup>15</sup>. The Q493K/R and E484K substitutions are located in the RBD region  
184 of the spike protein, and associated with resistance to monoclonal antibodies or convalescent  
185 plasma<sup>16,17</sup>. In particular, the E484K mutation has been linked to the rapid spread of B.1.351  
186 and B.1.1.28 variants in South Africa and Brazil, respectively. To date, over 17,000 E484K  
187 variants have been identified from >60 countries within various SARS-CoV2 lineages  
188 ([www.gisaid.org](http://www.gisaid.org)) (**Fig2**), potentially posing significant challenges to vaccine efficacy and  
189 increased reinfection risk. Intriguingly, the co-occurrence of 141-144LGVY and E484K in the  
190 third tracheal aspirate specimen completely replaced other mutants, suggesting this haplotype  
191 may have compensated for a fitness cost or have higher antibody resistance level.

## 192 193 **Discussion**

194 While most immunocompetent hosts are able to achieve resolution of COVID-19 within 1-3  
195 weeks after symptoms, there is emerging evidence that a pre-existing immunocompromised  
196 state is associated with prolonged infection and significantly increased risk of severe

197 disease<sup>4,5,18,19</sup>. Although the immunological mechanisms for control of SARS-CoV-2 in humans  
198 have not been clearly elucidated, it is likely that both cytotoxic T-cells and antibody-mediated  
199 immune responses are important for clearance of the viral infection<sup>18,20</sup>. Activation of type I and  
200 type III interferons has been postulated to be a key contributor to innate immune control<sup>20,21</sup>, in  
201 addition to CD8<sup>+</sup> effector T-cell-mediated killing of virally infected cells and CD4<sup>+</sup> T cell-  
202 dependent enhancement of CD8<sup>+</sup> and B-cell responses<sup>18,20</sup>. Following viral clearance, long-  
203 term memory T-cells are formed for prolonged antiviral immunity. Chronic viral infection must  
204 evade or suppress some part of this pathway. Moreover, animal studies have shown that  
205 chronic viral infections were characterized by persistent antigenic activation of T-cells, ultimately  
206 driving a nonresponsive cell state known as T-cell “exhaustion”. This state was often  
207 accompanied by lymphopenia<sup>20</sup>. This patient’s anti-rejection regimen of mycophenolate and  
208 tacrolimus targets and inhibits T-cell function and replication, and treatment with prednisone  
209 may compromise the ‘proliferative burst’ of effector T-cells<sup>22</sup>. While mycophenolate was  
210 discontinued, the patient was maintained on tacrolimus and prednisone during his entire  
211 hospitalization, which likely further impaired his cellular immunity against SARS-CoV-2. In our  
212 case, the treatment with convalescent plasma in combination with the routine maintenance of an  
213 anti-rejection regiment may have facilitated a “breeding ground” and the emergence of immune-  
214 escape mutants. Although we have no evidence that these two escape variants were  
215 transmitted, this case suggest that VOCs may arise among immunocompromised populations  
216 undergoing anti-SARS-CoV-2 therapy, and enhanced measures will be required to reduce  
217 transmission.

218

219 **Acknowledgement**

220 We gratefully acknowledge the Authors from the Originating laboratories responsible for  
221 obtaining the specimens and the Submitting laboratories where genetic sequence data were  
222 generated and shared via the GISAID Initiative, on which this research is based.

223

## 224 **Reference**

- 225 1. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7  
226 Lineage - United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep*  
227 2021;70:95-9.
- 228 2. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-  
229 2 and circulating variants. *bioRxiv* 2021:2021.01.15.426911.
- 230 3. Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations to  
231 the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum  
232 antibodies. *bioRxiv* 2021:2020.12.31.425021.
- 233 4. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an  
234 Immunocompromised Host. *N Engl J Med* 2020;383:2291-3.
- 235 5. Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: Prolonged Infectious SARS-  
236 CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell*  
237 2020;183:1901-12.e9.
- 238 6. Lombardi L, Turner SA, Zhao F, Butler G. Gene editing in clinical isolates of *Candida*  
239 parapsilosis using CRISPR/Cas9. *Scientific reports* 2017;7:8051.
- 240 7. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing  
241 reads. *EMBnetjournal* 2011;17:10-2.
- 242 8. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.  
243 *Bioinformatics* 2009;25:1754-60.

- 244 9. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and  
245 SAMtools. *Bioinformatics* 2009;25:2078-9.
- 246 10. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting the  
247 effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila*  
248 *melanogaster* strain w1118; iso-2; iso-3. *Fly* 2012;6:80-92.
- 249 11. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution.  
250 *Bioinformatics* 2018;34:4121-3.
- 251 12. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative  
252 contribution to global health. *Glob Chall* 2017;1:33-46.
- 253 13. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective  
254 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* 2015;32:268-  
255 74.
- 256 14. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new  
257 developments. *Nucleic Acids Res* 2019;47:W256-w9.
- 258 15. McCarthy KR, Rennick LJ, Nambulli S, et al. Recurrent deletions in the SARS-CoV-2  
259 spike glycoprotein drive antibody escape. *Science* 2021:eabf6950.
- 260 16. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-  
261 CoV-2 spike protein variants. *eLife* 2020;9.
- 262 17. Starr TN, Greaney AJ, Addetia A, et al. Prospective mapping of viral mutations that  
263 escape antibodies used to treat COVID-19. *Science* 2021.
- 264 18. Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an  
265 Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.  
266 *J Infect Dis* 2020;222:1103-7.
- 267 19. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide  
268 analysis in China. *Lancet Oncol* 2020;21:335-7.


269 20. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. *J Exp*  
270 *Med* 2020;217.

271 21. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity  
272 and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease  
273 after allogeneic T-cell-depleted stem cell transplantation. *Blood* 2000;95:2240-5.

274 22. Okoye IS, Xu L, Walker J, Elahi S. The glucocorticoids prednisone and dexamethasone  
275 differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune  
276 checkpoint blockade. *Cancer Immunol Immunother* 2020;69:1423-36.

277


278



279

280 **Fig1. Clinical and genomic characterization of SARS-CoV-2 variations in an**  
 281 **immunocompromised patient. (A),** Clinical timeline of events of the immunocompromised  
 282 patient. **(B),** SARS-CoV-2 genotypes of the major haplotypes from the swab (swab-1) and  
 283 tracheal aspirate samples (TA-1, day 7; TA-2, day 21 and TA-3, day 27). **(C),** The phylogenetic  
 284 clades of SARS-CoV-2 variants. The tree was generated using Nextclade  
 285 (clades.nextstrain.org). The nodes are highlighted by the Nextstrain clades. The clades  
 286 associated with E484K mutations are denoted by red arrows, while the B.1.369 genomes  
 287 described in this study are illustrated by a black arrow. **(D),** The mutation frequency changes  
 288 among the swab and tracheal aspirate samples over time.

289



290  
291 **Fig 2. Global distribution of S protein E484K mutation.** A maximum-likelihood phylogenetic  
292 tree with the 4 patient sequences (B.1.369) and 1,983 selected SARS-CoV-2 genomes from the  
293 GISAID database (date as 2/12/2021) is annotated using iTOL ([www.itol.embl.de](http://www.itol.embl.de)). The scale  
294 represents 0.0001 nucleotide substitutions per site. The SARS-CoV-2 Pangolin lineage and  
295 country are illustrated as two outer rings in different colors.

296

297

**Table 1 Cycle-threshold values of SARS-CoV-2 samples**

Sample	Ct for N2 target
Swab-1 (Day 0)	24.34
TA-1 (Day 7)	20.43
TA-2 (Day 21)	15.39
TA-3 (Day 27)	24.65
Swab-2 (Day 34)	37.14
Swab-3 (Day 41)	32.39

298

299